| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Apr 12, 2017 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 13,065 | $50.42 | $658,773.93 | -33.2% | |
| Apr 12, 2017 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 19,596 | $50.42 | $988,085.28 | -2.9% | |
| Apr 12, 2017 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 13,065 | $50.42 | $658,773.93 | -4.8% | |
| Apr 11, 2017 | LFCR Lifecore Biomedical, Inc. \de\ | Midyett Ronald Lane | Chief Operations Officer | Sell | 20,000 | $13.76 | $275,200.00 | -19.1% | |
| Apr 11, 2017 | LFCR Lifecore Biomedical, Inc. \de\ | Frank Fred | Director | Sell | 3,025 | $14.00 | $42,350.00 | -6.8% | |
| Apr 7, 2017 | CPIX Cumberland Pharmaceuticals Inc | Lawrence Thomas R | Director | Sell | 6,000 | $6.40 | $38,400.00 | -100% | |
| Apr 7, 2017 | LFCR Lifecore Biomedical, Inc. \de\ | Bitler Steven P | Vice President, Technology | Sell | 8,000 | $13.58 | $108,640.00 | -10.3% | |
| Apr 3, 2017 | ALKS Alkermes Plc. | Biberstein Kathryn L | Evp/ Cao/ CCO Alks Inc; Sec Alks | Sell | 15,000 | $57.68 | $865,233.59 | -8.1% | |
| Apr 3, 2017 | AKBA Akebia Therapeutics, Inc. | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,401 | $9.18 | $12,857.68 | -1.3% | |
| Apr 3, 2017 | AKBA Akebia Therapeutics, Inc. | Nash Duane | Director | Sell | 991 | $9.20 | $9,119.28 | -3.9% | |
| Apr 3, 2017 | MRK Merck & Co., Inc. | Schechter Adam H | EVP &Pres-global Human Health | Sell | 53,850 | $63.48 | $3,418,166.45 | -31.6% | |
| Apr 3, 2017 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Biodefense Divison | Sell | 11,419 | $28.62 | $326,808.35 | -30.5% | |
| Apr 3, 2017 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,500 | $58.31 | $87,465.00 | -15.8% | |
| Apr 3, 2017 | AKBA Akebia Therapeutics, Inc. | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,556 | $9.18 | $14,280.19 | -1.4% | |
| Apr 3, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Proquest Investments Iv, L.P. | 10% Owner | Sell | 91,332 | $83.09 | $7,589,014.38 | -0.8% | |
| Mar 31, 2017 | HYEX Healthy Extracts Inc. | Nejman Joseph | President | Buy | 33,466,044 | $0.00 | - | +126.3% | |
| Mar 30, 2017 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 210,000 | $84.67 | $17,781,540.00 | -0.2% | |
| Mar 29, 2017 | ALKS Alkermes Plc. | Cooke Shane62 | President, Alkermes Plc | Sell | 2,070 | $60.00 | $124,200.00 | -2.8% | |
| Mar 29, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Proquest Investments Iv, L.P. | 10% Owner | Sell | 106,468 | $83.01 | $8,837,576.19 | -0.9% | |
| Mar 23, 2017 | ALKS Alkermes Plc. | Cooke Shane62 | President, Alkermes Plc | Sell | 6,030 | $60.01 | $361,856.08 | -7.7% | |
| Mar 23, 2017 | CPIX Cumberland Pharmaceuticals Inc | Bonner Michael | Chief Financial Officer | Buy | 900 | $6.42 | $5,778.00 | +7.6% | |
| Mar 23, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Krill Steven L. | EVP &Chief Scientific Officer | Sell | 14,125 | $81.07 | $1,145,130.19 | -100% | |
| Mar 23, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Proquest Investments Iv, L.P. | 10% Owner | Sell | 1,200 | $83.05 | $99,657.00 | - | |
| Mar 22, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Edlin Richard A. | Director | Buy | 6,000 | $79.44 | $476,640.00 | +25.6% | |
| Mar 22, 2017 | RMTI Rockwell Medical, Inc. | Richmond David S. | 10% Owner, See Footnote 1 | Buy | 37,210 | $5.84 | $217,491.54 | +86.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.